Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05587998 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Effect of AZD4041 on Respiratory Drive in Recreational Opioid Users.
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT05587998 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 45 participants.
The verdict
NCT05587998, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
This is a Phase 1, single-centre, randomized, double-blind, placebo-controlled, 2 fixed sequences, multiple dose study in healthy male and/or female recreational opioid users. This study is being primarily conducted to assess the effect on respiratory drive of morphine administered after multiple doses of AZD4041 compared to morphine administered alone in healthy recreational opioid users. The study will include up to 44 participants who will be randomized to either AZD4041 and morphine (28 participants) or placebo and morphine (16 participants). This is to ensure completion of at least 36 participants (24 AZD4041 + morphine, and 12 Placebo + morphine on Day 15). The total study duration will be up to 54 days (including screening) per participant.
Interventions
- OTHER Placebo
- DRUG Morphine
- DRUG AZD4041
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2022-08-31 |
| Est. Completion | 2023-05-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05587998
The ClinicalTrials.gov registry entry for NCT05587998 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05587998 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05587998 about?
NCT05587998 is a clinical study titled "A Study to Assess the Effect of AZD4041 on Respiratory Drive in Recreational Opioid Users.". This is a Phase 1, single-centre, randomized, double-blind, placebo-controlled, 2 fixed sequences, multiple dose study in healthy male and/or female recreational opioid users. This study is being primarily conducted to assess the effect on respiratory drive of morphine administered after multiple d...
What is the current status of trial NCT05587998?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2022-08-31. Estimated completion is 2023-05-25.
What interventions are being tested in trial NCT05587998?
The interventions under investigation include: Placebo (OTHER), Morphine (DRUG), AZD4041 (DRUG).
Who is sponsoring clinical trial NCT05587998?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.